CDK9 and glioblastoma: Currently, CDK9-targeting is investigated as a second-line agent in a phase I trial metastatic or progressive solid tumors and also in recurrent and in newly diagnosed IDH1R132H-non-mutant anaplastic astrocytoma or GBM (STable 2).